
NYSE:MRK
This summary was created by AI, based on 23 opinions in the last 12 months.
Merck & Company (MRK) is recognized for its strong performance, particularly bolstered by its cancer treatment drug, Keytruda, which is a significant revenue driver but faces a looming patent cliff. Despite concerns regarding the future of Keytruda, many experts are optimistic about the company's robust drug pipeline and strategic acquisitions that should help mitigate the risks associated with the loss of this key drug. The consensus among analysts suggests solid revenue growth potential, with expectations that the company will release a considerable number of new drugs by 2030. Additionally, Merck is committed to returning capital to shareholders, which includes stock buybacks and steady dividends, positioning the company as a quality investment in the healthcare sector.
Keytruda makes up half of sales, which makes the market nervous, because the drug faces a patent cliff in a few years. Their pipeline is deep, and the acquisitions they made will replenish that pipeline. Even when it goes off-patent, Keytruda will remain a preferred drug by doctors.
Today's downward move isn't all that outsized. There's been more clarity on US drug pricing. Seeing a bit of market exhaustion, as US pharma is trading at huge premiums relative to their own history.
Rerating from pricing clarity has already been baked in. R&D pipeline in the sector is a mixed bag, doesn't trust it.
Merck & Company is a American stock, trading under the symbol MRK (previously MRK-N on Stockchase) on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK
In the last year, 23 stock analysts issued a Buy, Sell, or Hold rating on MRK (previously MRK-N on Stockchase). 17 analysts recommended to BUY and 3 analysts recommended to SELL the stock. The latest stock analyst rating is PAST TOP PICK. Read the latest stock experts' ratings for Merck & Company.
Merck & Company was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-07-23. Read the latest stock experts ratings for Merck & Company.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Merck & Company.
Merck & Company is followed by 311 investors on Stockchase and is a trending stock that is worth watching.
On 2026-07-31, Merck & Company (MRK) stock closed at a price of $130.20.
Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $110) to $121 at this time.